Pan-European disputes once again piqued JUVE Patent readers' interest over 2022, with this year's top ten most-read articles leading with the case between Sandoz, Teva and Novartis over apixaban. Medical devices also came to the fore in the multi-patent action between Dexcom and Abbott, while Munich Regional Court's approach to connected cars and FRAND got the market talking. However, Nokia against Oppo is by the far the most popular case for JUVE Patent's readers over 2022 – not forgetting further changes at the EPO, as well as the market closely following more developments at the UPC.
27 December 2022 by Amy Sandys
These are the ten most-read articles by JUVE Patent readers in 2022: